Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Dexcom Addresses G7 Quality Issues, Unveils New Features for Type 2 Diabetes Management

Dexcom, a leader in continuous glucose monitoring (CGM) technology, has reported significant progress in addressing quality issues with its G7 sensor and unveiled new developments for Type 2 diabetes management. The company's executives provided updates on these developments during a recent earnings call, highlighting improvements in product quality and customer service, as well as introducing new features aimed at expanding their market reach.

NoahAI News10/31/2025

Corporate Venture Firms Step Up Biotech Funding Amid Industry Slowdown

In a striking shift within the biotechnology startup ecosystem, corporate venture firms have emerged as key players filling the funding gap left by traditional investors. This development comes amid a prolonged slowdown in biotechnology startup funding, offering a lifeline to early-stage companies navigating an increasingly challenging financial landscape.

NoahAI News10/31/2025

Nanobiotix Secures $71 Million in Non-Dilutive Funding for Cancer Drug Development

Nanobiotix, a biotechnology company developing innovative cancer treatments, has announced a significant financial boost through a $71 million non-dilutive funding agreement with HealthCare Royalty (HCRx). This strategic move aims to support the ongoing development of JNJ-1900, also known as NBTXR3, a promising cancer drug currently in phase 3 trials.

NoahAI News10/31/2025

4DMT Secures $420M Deal with Otsuka for Retinal Gene Therapy Rights

4D Molecular Therapeutics (4DMT) has announced a significant partnership with Otsuka Pharmaceutical, selling the Asia-Pacific rights to its promising eye gene therapy, 4D-150. The deal, valued at up to $420 million, provides 4DMT with substantial funding to advance the therapy's phase 3 development for retinal vascular diseases.

NoahAI News10/31/2025

Young Biotech Executive's Rise Exemplifies Industry's Dynamic Leadership

Neena Bitritto-Garg, CEO of Ensho Therapeutics and recent addition to BioSpace's 40 Under 40 list, has rapidly ascended the ranks of the biotech industry, demonstrating the sector's appetite for bold, innovative leadership. Her journey from Wall Street analyst to biotech executive offers insight into the evolving landscape of pharmaceutical development and the critical role of strategic partnerships.

NoahAI News10/31/2025

Illumina Sees Flat Q3 Revenue Amid China Challenges, Eyes Growth Opportunities

Illumina, the global leader in DNA sequencing technology, reported flat revenue for the third quarter of 2025, as the company continues to navigate challenges in the Chinese market. Despite these headwinds, CEO Jacob Thaysen remains optimistic about future growth prospects and ongoing dialogues with regulatory agencies.

NoahAI News10/31/2025

Pharmaceutical Industry Earnings Roundup: Mixed Results and Market Challenges

Alnylam Pharmaceuticals, a rising star in the biotechnology sector, reported impressive third-quarter results with revenues of $1.25 billion, surpassing analyst estimates by nearly $300 million. The company's flagship drug Amvuttra, used to treat transthyretin amyloidosis (TTR), generated $685 million in sales, exceeding expectations of $622 million.

NoahAI News10/31/2025

Lilly's Orforglipron: Balancing Accessibility and Innovation in the Weight Loss Drug Market

Eli Lilly is navigating a complex landscape as it prepares to launch its next-generation obesity drug, orforglipron. The company faces the challenge of making the medication accessible to patients while ensuring sufficient revenue to fuel future research and development efforts.

NoahAI News10/31/2025

Pharmaceutical Industry Faces Widespread Layoffs and Strategic Shifts Amid Challenging Market Conditions

The pharmaceutical industry is experiencing a significant wave of layoffs and strategic restructuring as companies grapple with challenging market conditions, pipeline setbacks, and the need to reallocate resources. This trend is affecting both large pharmaceutical companies and smaller biotech firms, with thousands of jobs impacted across the sector.

NoahAI News10/31/2025

Bristol Myers Squibb's Q3 Earnings: Cobenfy Challenges and Industry-Wide Pricing Discussions

Bristol Myers Squibb (BMS) reported better-than-expected third-quarter earnings, with total revenue of $12.2 billion. However, the company faced questions about the slow uptake of its recently approved schizophrenia drug, Cobenfy, and ongoing discussions about drug pricing with the U.S. government.

NoahAI News10/31/2025

Biogen's Leqembi Shows Promise in Presymptomatic Alzheimer's, But Challenges Remain

Biogen and its partner Eisai are making strides in expanding the reach of their anti-amyloid Alzheimer's drug Leqembi, with promising developments in presymptomatic treatment and new formulations. However, the pharmaceutical giant faces hurdles in convincing doctors to adopt this paradigm-shifting approach to Alzheimer's care.

NoahAI News10/31/2025

Teladoc Expands Insurance Coverage for BetterHelp Amid Financial Challenges

Teladoc Health, a leading virtual care provider, has announced plans to significantly expand insurance coverage for its direct-to-consumer mental health unit, BetterHelp. This strategic move comes as the company faces financial headwinds and aims to revitalize its mental health segment.

NoahAI News10/31/2025

«1 2 3 4...67 »